4569
KYORIN Pharmaceutical Co.,Ltd.
杏林製薬
- Industry
- Pharmaceutical
- Market
- Prime
- Accounting standards
- Japanese GAAP
- Consolidation basis
- Consolidated
Key metrics
Revenue(million JPY)
Mar 2021
102,904
Mar 2022
105,534
Mar 2023
113,270
Mar 2024
119,532
Mar 2025
130,087
Operating profit(million JPY)
Mar 2021
5,786
Mar 2022
5,007
Mar 2023
5,123
Mar 2024
6,013
Mar 2025
12,567
Operating profit margin(%)
Mar 2021
5.62
Mar 2022
4.74
Mar 2023
4.52
Mar 2024
5.03
Mar 2025
9.66
Profit before tax(million JPY)
Mar 2021
8,352
Mar 2022
5,216
Mar 2023
6,906
Mar 2024
7,019
Mar 2025
12,770
Profit(million JPY)
Mar 2021
6,130
Mar 2022
3,932
Mar 2023
4,723
Mar 2024
5,322
Mar 2025
9,086
Total assets(million JPY)
Mar 2021
167,126
Mar 2022
171,924
Mar 2023
176,045
Mar 2024
177,679
Mar 2025
193,618
Cash and cash equivalents(million JPY)
Mar 2021
26,476
Mar 2022
26,289
Mar 2023
18,816
Mar 2024
13,886
Mar 2025
15,021
Cash flows from operating activities(million JPY)
Mar 2021
5,189
Mar 2022
6,346
Mar 2023
2,008
Mar 2024
1,549
Mar 2025
3,506
Cash flows from investing activities(million JPY)
Mar 2021
-4,259
Mar 2022
-2,560
Mar 2023
-6,275
Mar 2024
-3,187
Mar 2025
-6,323
Cash flows from financing activities(million JPY)
Mar 2021
-4,918
Mar 2022
-4,112
Mar 2023
-3,363
Mar 2024
-3,347
Mar 2025
3,952
Return on equity(%)
Mar 2021
5
Mar 2022
3.2
Mar 2023
3.8
Mar 2024
4.2
Mar 2025
6.8
Equity ratio(%)
Mar 2021
74.6
Mar 2022
72.4
Mar 2023
71.3
Mar 2024
73.6
Mar 2025
70.4
Earnings per share(JPY per share)
Mar 2021
106.99
Mar 2022
68.62
Mar 2023
82.44
Mar 2024
92.74
Mar 2025
158.17
Net assets per share(JPY per share)
Mar 2021
2,175.52
Mar 2022
2,172.83
Mar 2023
2,189.4
Mar 2024
2,276.52
Mar 2025
2,372.29
Dividend per share(JPY per share)
Mar 2021
75
Mar 2022
52
Mar 2023
52
Mar 2024
52
Mar 2025
57
Payout ratio(%)
Mar 2021
70.1
Mar 2022
75.78
Mar 2023
63.08
Mar 2024
56.07
Mar 2025
36.04
Disclaimer
The financial information and metrics on this page are based on publicly available filings and other public sources. We do not guarantee their accuracy, completeness, or timeliness.
The information on this page is provided for reference purposes only and does not constitute a recommendation to buy or sell any security. Investment decisions should be made at your own responsibility.